Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 9/20 | 0.46 |
| ▸ | CTSB | P07858 | 5/20 | 0.46 |
| ▸ | CTSL | P07711 | 4/20 | 0.46 |
| ▸ | CTSS | P25774 | 3/20 | 0.46 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.45 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.45 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2140167 | 0.93 | CTSK (0.48) | CTSKCTSBCTSLCTSSPSMB1 | |
| SCHEMBL6014225 | 0.91 | CTSK (0.44) | CTSKCTSBCTSLCTSSPSMB1 | |
| SCHEMBL1014662 | 0.88 | CTSB (0.44) | CTSKCTSBCTSLCTSSPSMB1 | |
| SCHEMBL26910148 | 0.85 | CTSK (0.56) | CTSKCTSBCTSLCTSSPSMB1 | |
| SCHEMBL19400126 | 0.85 | CTSK (0.56) | CTSKCTSBCTSLCTSSPSMB1 | |
| SCHEMBL28288627 | 0.85 | CTSK (0.56) | CTSKCTSBCTSLCTSSPSMB1 | |
| SCHEMBL28034519 | 0.83 | CTSK (0.49) | CTSKCTSBCTSLCTSS | |
| SCHEMBL8586811 | 0.81 | CTSB (0.47) | CTSKCTSBCTSLCTSSPSMB1 | |
| SCHEMBL11209394 | 0.80 | CTSK (0.58) | CTSKCTSBCTSLCTSS | |
| SCHEMBL27824395 | 0.80 | CTSK (0.58) | CTSKCTSBCTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| WO-2024118561-A2 | DYSREGULATION OF NEUROPROTEASOMES BY APOE ISOFORMS DRIVES ENDOGENOUS TAU AGGREGATION | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-06-06 | — | — | WO | claimed |
| EP-4313144-A1 | COMBINATIONS COMPRISING ANTI-TM4SF1 ANTIBODIES AND IMMUNOTHERAPEUTIC AGENTS AND METHODS OF USING THE SAME | Angiex, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| US-20230293713-A1 | ANTI-TM4SF1 ANTIBODY DRUG CONJUGATES AND METHODS OF USING SAME | ANGIEX, INC. | 2023-09-21 | — | — | US | claimed |
| WO-2022204565-A1 | COMBINATIONS COMPRISING ANTI-TM4SF1 ANTIBODIES AND IMMUNOTHERAPEUTIC AGENTS AND METHODS OF USING THE SAME | ANGIEX, INC. (US) | 2022-09-29 | — | — | WO | claimed |
| EP-3319965-B1 | NOVEL COMPOUNDS FOR USE IN TREATING OR PREVENTING CANCEROUS DISEASES | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS (GR) | 2022-05-04 | — | — | EP | claimed |
| WO-2021222783-A1 | ANTI-TM4SF1 ANTIBODY DRUG CONJUGATES AND METHODS OF USING SAME | ANGIEX, INC. (US) | 2021-11-04 | — | — | WO | claimed |
| US-20210246120-A1 | METHOD OF PREPARATION AND USE OF PHOSPHOINOSITIDE 3-KINASE INHIBITORS IN TREATING CANCER | FOUNDATION FOR RESEARCH AND TECHNOLOGY HELLAS (FORTH) (GR) | 2021-08-12 | — | — | US | claimed |
| EP-3841097-A1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | Biomedical Research Foundation of the Academy of Athens (GR) | 2021-06-30 | — | — | EP | claimed |
| WO-2020039097-A1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RESEARCH FOUNDATION OF THE ACADEMY OF ATHENS (BRFAA) (GR) | 2020-02-27 | — | — | WO | claimed |
| EP-2078201-A2 | DENGUE DIAGNOSIS AND TREATMENT | Agency for Science, Technology and Research (SG) | 2009-07-15 | — | — | EP | claimed |
| US-20080248097-A1 | POLYMERIC MICELLES FOR COMBINATION DRUG DELIVERY | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2008-10-09 | — | — | US | claimed |
| WO-2008106129-A2 | POLYMERIC MICELLES FOR COMBINATION DRUG DELIVERY | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-09-04 | — | — | WO | claimed |
| WO-2008041953-A2 | DENGUE DIAGNOSIS AND TREATMENT | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2008-04-10 | — | — | WO | claimed |
| US-20080045495-A1 | Treatment of Patients with Cystic Disease by Alteration of Fibrocystin Proteolysis | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-02-21 | — | — | US | claimed |
| US-7238659-B2 | Reducing axon degeneration with proteasome inhibitors | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2007-07-03 | — | — | US | claimed |
| US-20060074028-A1 | Reducing axon degeneration with proteasome inhibitors | CHILDREN'S MEDICAL CENTER CORP | 2006-04-06 | — | — | US | claimed |
| US-7012063-B2 | Reducing axon degeneration with proteasome inhibitors | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2006-03-14 | — | — | US | claimed |
| WO-2005014783-A2 | REDUCING AXON DEGENERATION WITH PROTEASOME INHIBITORS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2005-02-17 | — | — | WO | claimed |
| US-20040254118-A1 | Reducing axon degeneration with proteasome inhibitors | CHILDREN'S MEDICAL CENTER CORPORATION | 2004-12-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246120-A1 | METHOD OF PREPARATION AND USE OF PHOSPHOINOSITIDE 3-KINASE INHIBITORS IN TREATING CANCER | PIK3R3, PIK3CA, PIK3C2A | CTSK 4085/4885CTSB 4058/4885CTSL 4307/4885 |
| US-20080248097-A1 | POLYMERIC MICELLES FOR COMBINATION DRUG DELIVERY | MCL1, NUP205, ABCB1 | CTSK 3999/4885CTSB 1020/4885CTSL 3552/4885 |
| US-20080045495-A1 | Treatment of Patients with Cystic Disease by Alteration of Fibrocystin Proteolysis | PKD1, CAPN1, PKD2 | CTSK 60/4885CTSB 40/4885CTSL 70/4885 |
| US-20230293713-A1 | ANTI-TM4SF1 ANTIBODY DRUG CONJUGATES AND METHODS OF USING SAME | TM9SF4, TM9SF2, TM9SF3 | CTSK 1456/4885CTSB 2080/4885CTSL 1614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.